Danazol
Brand names: Danol
Danazol is a synthetic androgen derivative with anti-gonadotrophic activity used in endometriosis, benign fibrocystic breast disease, and hereditary angioedema.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It suppresses the pituitary release of gonadotrophins and has weak androgenic effects, reducing ovarian hormone production and inducing an anovulatory, hypo-oestrogenic state.
Prescribing in practice
- It can cause androgenic adverse effects including weight gain, acne, hirsutism, and voice deepening, some of which may be irreversible, so women should be warned and treatment reviewed if virilisation occurs.
- It is contraindicated in pregnancy because of the risk of virilising a female fetus, and effective non-hormonal contraception must be used throughout treatment.
- Use with caution where there is hepatic impairment, cardiac or renal disease, or a history of thromboembolism, and avoid in undiagnosed abnormal genital bleeding.
Monitoring
Monitor liver function during treatment and watch for androgenic effects, weight gain, and signs of thromboembolism.
Counselling the patient
- Report any deepening of the voice promptly, as this change may not fully reverse.
- Use a reliable non-hormonal method of contraception, and stop the medicine and seek advice if you think you may be pregnant.
- Tell your doctor about any abdominal pain, jaundice, or unusual swelling.
Evidence & guidelines
Danazol is an established but second-line hormonal treatment for endometriosis, generally reserved for when better-tolerated options are unsuitable because of its androgenic adverse-effect profile.
Reference: SmPC Danol; ESHRE Endometriosis Guideline 2022; HAE UK Consensus Document; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Spinal Anaesthesia Hypotension Management · AAGBI; ASA
- Pre-Eclampsia / Eclampsia in ED · NICE NG133; RCOG Green-top 10A
- Suspected Ectopic Pregnancy · NICE NG126; RCOG Green-top 21
- Polycystic Ovary Syndrome (PCOS) · International PCOS Guideline 2023; NICE CKS
- Pre-eclampsia Management · NICE NG133 2019
- Ectopic Pregnancy · NICE CG154 / RCOG GTG 21